1/@RANDCorporation just put out a report on drug prices amongst the G7, and the methodology is somewhat appalling. I'm kind of hoping @DrugChannels looks at it because it contains such glaring errors worthy of an Adam Fein Policy Roast.

2/In the introduction of the report (p.viii) they admit that they can't actually compare prices of drugs because US drugs include rebates and many of those aren't public info. So they start out the report by saying they're going to use incorrect numbers....

3/"Although prices net of rebates and other discounts paid by manufacturers after drugs are dispensed are particularly relevant in the United States, these prices are generally not available to researchers."

4/Honestly the report should have stopped right there. How do you honestly proceed after such a whopper of a flaw in your own methodology? What's worse is they buried the useful observation

5/"for unbranded generic drugs (with U.S.
prices at 84 percent of those in comparison countries). Unbranded generics represent 84 percent
of volume in the United States, compared with 35 percent of volume for the other OECD
countries in the study."